Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment

Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment

Acute kidney injury and chronic kidney disease is common in multiple myeloma. Fludarabine which is part of lymphodepletion before CAR-T cell therapy is renally eliminated and its use is not recommended for patients with severe renal impairment defined as a glomerular filtration rate below 30ml/min/1...

Full description

Bibliographic Details
Main Authors: Franziska Marquard, Claudia Langebrake, Dietlinde Janson, Maida Mahmud, Adrin Dadkhah, Nicolaus Kröger, Francis Ayuk
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Oncology
Subjects:
CAR-T-cell therapy
lymphodepletion
GFR < 30ml/min
fludarabine
cyclophosphamide
dialysis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1288764/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1288764/full

Similar Items